Cargando…
Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176012/ https://www.ncbi.nlm.nih.gov/pubmed/36823411 http://dx.doi.org/10.1111/cts.13496 |
| _version_ | 1785040343209607168 |
|---|---|
| author | Subramaniam, Sriram Shord, Stacy S. Leong, Ruby Norsworthy, Kelly Rahman, Atiqur Booth, Brian Okusanya, Olanrewaju |
| author_facet | Subramaniam, Sriram Shord, Stacy S. Leong, Ruby Norsworthy, Kelly Rahman, Atiqur Booth, Brian Okusanya, Olanrewaju |
| author_sort | Subramaniam, Sriram |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10176012 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101760122023-05-13 Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development Subramaniam, Sriram Shord, Stacy S. Leong, Ruby Norsworthy, Kelly Rahman, Atiqur Booth, Brian Okusanya, Olanrewaju Clin Transl Sci Perspectives John Wiley and Sons Inc. 2023-02-23 /pmc/articles/PMC10176012/ /pubmed/36823411 http://dx.doi.org/10.1111/cts.13496 Text en Published 2023. This article is a U.S. Government work and is in the public domain in the USA. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Perspectives Subramaniam, Sriram Shord, Stacy S. Leong, Ruby Norsworthy, Kelly Rahman, Atiqur Booth, Brian Okusanya, Olanrewaju Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development |
| title | Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development |
| title_full | Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development |
| title_fullStr | Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development |
| title_full_unstemmed | Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development |
| title_short | Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development |
| title_sort | study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development |
| topic | Perspectives |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176012/ https://www.ncbi.nlm.nih.gov/pubmed/36823411 http://dx.doi.org/10.1111/cts.13496 |
| work_keys_str_mv | AT subramaniamsriram studydesignconsiderationstoassesstheimpactofpotentialdrugdruginteractionsinfirstinhumanstudiesinoncologydrugdevelopment AT shordstacys studydesignconsiderationstoassesstheimpactofpotentialdrugdruginteractionsinfirstinhumanstudiesinoncologydrugdevelopment AT leongruby studydesignconsiderationstoassesstheimpactofpotentialdrugdruginteractionsinfirstinhumanstudiesinoncologydrugdevelopment AT norsworthykelly studydesignconsiderationstoassesstheimpactofpotentialdrugdruginteractionsinfirstinhumanstudiesinoncologydrugdevelopment AT rahmanatiqur studydesignconsiderationstoassesstheimpactofpotentialdrugdruginteractionsinfirstinhumanstudiesinoncologydrugdevelopment AT boothbrian studydesignconsiderationstoassesstheimpactofpotentialdrugdruginteractionsinfirstinhumanstudiesinoncologydrugdevelopment AT okusanyaolanrewaju studydesignconsiderationstoassesstheimpactofpotentialdrugdruginteractionsinfirstinhumanstudiesinoncologydrugdevelopment |